{"id":12613,"date":"2021-09-07T16:20:33","date_gmt":"2021-09-07T14:20:33","guid":{"rendered":"https:\/\/www.bm-t.de\/2021\/bmt-investee-partner-inflarx-selected-for-covid-19-therapy-offensive-of-the-german-federal-ministry-of-education-and-research\/"},"modified":"2021-09-08T09:45:33","modified_gmt":"2021-09-08T07:45:33","slug":"inflarx-selected-for-covid-19-therapy-offensive-of-the-german-federal-ministry-of-education-and-research","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2021\/inflarx-selected-for-covid-19-therapy-offensive-of-the-german-federal-ministry-of-education-and-research\/","title":{"rendered":"bm|t Investee Partner InflaRx selected for COVID-19 Therapy Offensive of the German Federal Ministry of Education and Research"},"content":{"rendered":"

The Ger\u00adman Fed\u00aderal Min\u00adistry of Edu\u00adca\u00adtion and Research has announced the first six funded biotech com\u00adpa\u00adnies in its COVID-19 ther\u00adapy ini\u00adtia\u00adtive, which is being funded with up to \u20ac300 mil\u00adlion. The fund\u00ading is intended to finan\u00adcially accel\u00ader\u00adate Phase IIb and Phase III stud\u00adies to improve med\u00adical care for patients with the disease.<\/p>\n

In addi\u00adtion to NAS\u00adDAQ-listed InflaRx (Nas\u00addaq: IFRX) \u2014 an Investee Part\u00adner of bm|t \u2014 other com\u00adpa\u00adnies selected for fund\u00ading include AdrenoMed AG, Apogenix AG, Atriva Ther\u00ada\u00adpeu\u00adtics GmbH, CORAT Ther\u00ada\u00adpeu\u00adtics GmbH and DRK Baden-W\u00fcrt\u00adtem\u00adberg-Hes\u00adsen gGmbH. These can\u00addi\u00addates are devel\u00adop\u00ading drugs to stop viral repli\u00adca\u00adtion in the early stages of the dis\u00adease, as well as can\u00addi\u00addates to help alle\u00advi\u00adate the severe immune-related symp\u00adtoms of later stages of COVID.<\/p>\n

\u201cAt this point, only vac\u00adci\u00adna\u00adtion against Corona will help,\u201d said Ger\u00adman Health Min\u00adis\u00adter Jens Spahn. \u201cBut we also want to take the hor\u00adror out of the pan\u00addemic in the long term. That\u2019s why we are pro\u00admot\u00ading the devel\u00adop\u00adment of new drugs so that we can con\u00adtinue to treat Corona patients well in the future. And we\u2019re invest\u00ading in the future because we\u2019re also strength\u00aden\u00ading Ger\u00admany\u2019s posi\u00adtion as a research and devel\u00adop\u00adment loca\u00adtion in the field of biotech\u00adnol\u00adogy.\u201d Fed\u00aderal Research Min\u00adis\u00adter Anja Kar\u00adliczek said, \u201cEven with wide\u00adspread avail\u00adabil\u00adity of COVID-19 vac\u00adcines, not every\u00adone will be able to receive a vac\u00adci\u00adna\u00adtion. There\u00adfore, more effec\u00adtive drugs are needed to treat suf\u00adfer\u00aders. Due to the vary\u00ading sever\u00adity and stages of the dis\u00adease, patients require dif\u00adfer\u00adent ther\u00ada\u00adpies. Con\u00adse\u00adquently, a broad treat\u00adment reper\u00adtoire is needed.\u201d<\/p>\n

About InflaRx N.V.:<\/strong><\/h5>\n

InflaRx (Nas\u00addaq: IFRX) is a clin\u00adi\u00adcal-stage bio\u00adphar\u00adma\u00adceu\u00adti\u00adcal com\u00adpany focused on apply\u00ading its pro\u00adpri\u00adetary anti-C5a tech\u00adnol\u00adogy to dis\u00adcover and develop first-in-class, potent and spe\u00adcific inhibitors of C5a. Com\u00adple\u00adment C5a is a pow\u00ader\u00adful inflam\u00adma\u00adtory medi\u00ada\u00adtor involved in the pro\u00adgres\u00adsion of a wide vari\u00adety of autoim\u00admune and other inflam\u00adma\u00adtory dis\u00adeases. InflaRx was founded in 2007, and the group has offices and sub\u00adsidiaries in Jena and Munich, Ger\u00admany, as well as Ann Arbor, MI, USA.<\/p>\n

For fur\u00adther infor\u00adma\u00adtion please visit www.inflarx.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Ger\u00adman Fed\u00aderal Min\u00adistry of Edu\u00adca\u00adtion and Research has announced the first six funded biotech com\u00adpa\u00adnies in its COVID-19 ther\u00adapy ini\u00adtia\u00adtive, which is being funded with up to \u20ac300 mil\u00adlion. The fund\u00ading is intended to finan\u00adcially accel\u00ader\u00adate Phase IIb and Phase III stud\u00adies to improve med\u00adical care for patients with the dis\u00adease. In addi\u00adtion to [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":12878,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[3],"tags":[171,177,179,210,155],"class_list":["post-12613","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-3","tag-thuringia","tag-bmt-en","tag-covid-19-en","tag-investeepartner","tag-corona-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/12613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=12613"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/12613\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/12878"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=12613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=12613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=12613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}